Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Johnson Fistel is investigating Capricor Therapeutics for potential securities law violations following FDA staff concerns about the company's deramiocel heart therapy trial data. The FDA raised questions about how Capricor changed its measurement methodology post-trial and whether the trial population actually had the targeted heart condition. The stock declined approximately 70% on July 27, 2026, following the Reuters report of these FDA concerns.